<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881946</url>
  </required_header>
  <id_info>
    <org_study_id>PKB112835</org_study_id>
    <nct_id>NCT00881946</nct_id>
  </id_info>
  <brief_title>Repeat Dose Safety Study for Compound to Treat Hematologic Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accenture</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accenture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability of repeat doses of
      compound GSK2110183 in subjects with hematologic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical exam</measure>
    <time_frame>Screening, Days -3, 8, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Days -3, -2, -1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Screening, Days -3, -2, -1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans</measure>
    <time_frame>Screening, Additionally as needed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory assessments</measure>
    <time_frame>Screening, Days -3, 1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG Peformance Status</measure>
    <time_frame>Screening, Days -3, 8, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Maximum observed plasma concentraion (Cmax)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - time to Cmax [tmax] (Maximum observed plasma concentration)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Area under the plasma concentration-time curve (AUC(0-t))</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Apparent terminal phase elimination rate constant</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Apparent terminal phase half-life (t1/2)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - oral clearance (CL/F)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite Profiling</measure>
    <time_frame>Days -3, 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>GSK2119183</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK21110183</intervention_name>
    <description>Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops</description>
    <arm_group_label>GSK2119183</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent is provided.

          2. Male or female who is at least 18 years of age or older.

          3. Histologically- or cytologically-confirmed diagnosis of a hematologic malignancy -
             that has relapsed or is refractory after standard therapy, AND that is not associated
             with human immunodeficiency virus (HIV) infection or solid organ transplant,
             including:

               -  chronic lymphocytic leukemia (CLL),

               -  chronic myelogenous leukemia (CML),

               -  multiple myeloma (MM),

               -  non-Hodgkin's lymphoma (NHL),

               -  Hodgkin's lymphoma, or

               -  Other hematologic malignancy excluding:

               -  acute leukemia of any type

               -  CML blast crisis

               -  myelodysplastic syndrome (MDS)

               -  myelofibrosis

          4. Performance Status score of 0 and 1 according to the Eastern Cooperative Oncology
             Group (ECOG) scale

          5. Able to swallow and retain oral medication.

          6. Fasting serum glucose &lt; 126 mg/dL (&lt;7 mmol/L).

          7. Male subjects with a female partner of childbearing potential must have had a prior
             vasectomy or agree to use adequate contraception from the time of the first dose of
             study drug until three months after the last dose of study drug.

          8. A female subject is eligible to participate if she is of:

               -  Non-childbearing potential

               -  Child-bearing potential, has a negative serum pregnancy test during the screening
                  period, and agrees to use adequate contraception from screening until four weeks
                  after the last dose of study drug.

          9. Adequate organ system function

        Exclusion Criteria:

          1. Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior
             nitrosoureas or mitomycin C) prior to the first dose of study drug.

          2. Use of an investigational anti-cancer drug within 28 days or five half-lives,
             whichever is longer, preceding the first dose of study drug.

          3. Current use of a prohibited medication or requires any of these medications during
             treatment with study drug.

          4. Current use of anticoagulants at therapeutic levels within seven days prior to the
             first dose of study drug, including warfarin, low molecular weight heparin and direct
             thrombin inhibitors. Low dose (prophylactic) anticoagulants are permitted provided
             that subject's PT and PTT meet entry criteria.

          5. Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other than
             aspirin (81 mg daily).

          6. Presence of active gastrointestinal disease or other condition that could affect
             gastrointestinal absorption (e.g. malabsorption syndrome) or predispose subject to
             gastrointestinal ulceration.

          7. Any major surgery within the last four weeks.

          8. Unresolved toxicity (except alopecia) Grade 2 from previous anti-cancer therapy unless
             agreed to by a Medical Monitor and the Investigator

          9. Previously diagnosed diabetes mellitus (Type 1 or 2).

         10. Current use of oral corticosteroids, with the exception of inhaled or topical
             corticosteroids.

         11. Any serious or unstable pre-existing medical, psychiatric, or other condition
             (including lab abnormalities) that could interfere with subject safety or with
             obtaining informed consent.

         12. Symptomatic or untreated central nervous system (CNS) involvement by the hematologic
             malignancy (including primary CNS lymphoma).

         13. Evidence of severe or uncontrolled systemic diseases

         14. Known infection with HIV, HBV or HCV.

         15. QTc interval â‰¥ 470 msecs.

         16. Other clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd
             degree atrioventricular (AV) block.

         17. History of myocardial infarction, acute coronary syndromes (including unstable
             angina), coronary angioplasty, or stenting or bypass grafting within the past six
             months.

         18. Class III or IV heart failure as defined by the New York Heart Association (NYHA)
             functional classification system.

         19. Pregnant or lactating female.

         20. Active drug or alcohol abuse.

         21. History of sensitivity to heparin or heparin-induced thrombocytopenia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Jamie Freedman, MD, PhD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>aggressive lymphoma</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

